Description: Vaxcyte, Inc. a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is based in Foster City, California.
Home Page: vaxcyte.com
PCVX Technical Analysis
825 Industrial Road
San Carlos,
CA
94070
United States
Phone:
650 837 0111
Officers
| Name | Title |
|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director |
| Mr. Andrew L. Guggenhime M.B.A. | Pres, CFO & Principal Accounting Officer |
| Mr. James Wassil M.B.A., M.S. | Exec. VP & COO |
| Mr. Paul W. Sauer M.B.A., MBA | Sr. VP of Process Devel. & Manufacturing |
| Mr. Harp Dhaliwal M.B.A. | Sr. VP of Commercial Manufacturing & Supply Chain |
| Dr. Ashish Khanna M.B.A., Ph.D. | Co-Founder and Chief Bus. Officer |
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research |
| Ms. Janet Graesser | VP of Corp. Communications & Investor Relations |
| Mr. Mikhail Eydelman J.D. | Sr. VP, Gen. Counsel & Corp. Sec. |
| Karen Alderete | Exec. Director of HR |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.0497 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-06-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 89 |